NGM·Healthcare·$1.6B·#464 / 520 in Healthcare
NTLA Intellia Therapeutics, Inc.
21HIGH RISK
CATEGORY BREAKDOWN
GROWTH27
QUALITY0
STABILITY35
VALUATION6
GOVERNANCE30
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+16.9%
27
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
5 months
8
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
13.9%
89
< 25% strong
Price / Sales
Market cap relative to trailing revenue
24.3x
6
< 3x strong
Rule of 40
Growth rate plus operating margin
-635
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.1%
33
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+14.9%
25
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE NTLA WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when NTLA's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.